PL371437A1 - Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions - Google Patents
Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditionsInfo
- Publication number
- PL371437A1 PL371437A1 PL03371437A PL37143703A PL371437A1 PL 371437 A1 PL371437 A1 PL 371437A1 PL 03371437 A PL03371437 A PL 03371437A PL 37143703 A PL37143703 A PL 37143703A PL 371437 A1 PL371437 A1 PL 371437A1
- Authority
- PL
- Poland
- Prior art keywords
- alpha
- prevention
- treatment
- receptor antagonist
- combination therapy
- Prior art date
Links
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 title 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 230000001717 pathogenic effect Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35380102P | 2002-01-30 | 2002-01-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL371437A1 true PL371437A1 (en) | 2005-06-13 |
Family
ID=27663255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03371437A PL371437A1 (en) | 2002-01-30 | 2003-01-30 | Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20030199483A1 (enExample) |
| EP (1) | EP1469862A2 (enExample) |
| JP (1) | JP2005519918A (enExample) |
| KR (1) | KR20040096540A (enExample) |
| CN (1) | CN1625404A (enExample) |
| BR (1) | BR0307336A (enExample) |
| CA (1) | CA2474845A1 (enExample) |
| MX (1) | MXPA04007472A (enExample) |
| PL (1) | PL371437A1 (enExample) |
| WO (1) | WO2003063846A2 (enExample) |
| ZA (1) | ZA200405437B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100381163C (zh) * | 2006-08-29 | 2008-04-16 | 陈俊云 | 一种含利美尼定的药物 |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| WO2016141182A1 (en) | 2015-03-03 | 2016-09-09 | Yee Richard W | Compositions and methods for treating ocular diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5529992A (en) * | 1992-04-21 | 1996-06-25 | Curators Of The University Of Missouri | Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors |
| US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| JP2004501099A (ja) * | 2000-05-11 | 2004-01-15 | フアルマシア コーポレイション | アルドステロン頂点位相時の放出のためのアルドステロンアンタゴニスト組成物 |
| ES2265437T3 (es) * | 2000-07-27 | 2007-02-16 | Pharmacia Corporation | Terapia de combinacion antagonista epoxi-esteroidal de aldosterona y antagonista beta-adrenergico para tratamiento de la insuficiencia cardiaca congestiva. |
| KR20040080439A (ko) * | 2001-12-12 | 2004-09-18 | 파마시아 코포레이션 | 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법 |
-
2003
- 2003-01-30 CA CA002474845A patent/CA2474845A1/en not_active Abandoned
- 2003-01-30 EP EP20030710786 patent/EP1469862A2/en not_active Withdrawn
- 2003-01-30 US US10/354,653 patent/US20030199483A1/en not_active Abandoned
- 2003-01-30 BR BR0307336-0A patent/BR0307336A/pt not_active IP Right Cessation
- 2003-01-30 CN CNA03802988XA patent/CN1625404A/zh active Pending
- 2003-01-30 MX MXPA04007472A patent/MXPA04007472A/es unknown
- 2003-01-30 KR KR10-2004-7011714A patent/KR20040096540A/ko not_active Ceased
- 2003-01-30 JP JP2003563540A patent/JP2005519918A/ja not_active Abandoned
- 2003-01-30 PL PL03371437A patent/PL371437A1/xx not_active Application Discontinuation
- 2003-01-30 WO PCT/US2003/002723 patent/WO2003063846A2/en not_active Ceased
-
2004
- 2004-07-08 ZA ZA200405437A patent/ZA200405437B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1469862A2 (en) | 2004-10-27 |
| KR20040096540A (ko) | 2004-11-16 |
| ZA200405437B (en) | 2005-07-08 |
| WO2003063846A2 (en) | 2003-08-07 |
| US20030199483A1 (en) | 2003-10-23 |
| CN1625404A (zh) | 2005-06-08 |
| BR0307336A (pt) | 2004-12-07 |
| CA2474845A1 (en) | 2003-08-07 |
| WO2003063846A3 (en) | 2003-12-04 |
| JP2005519918A (ja) | 2005-07-07 |
| MXPA04007472A (es) | 2004-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200410011B (en) | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment | |
| AU2003268026A8 (en) | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions | |
| PL377344A1 (pl) | Lekarstwo do profilaktyki i leczenia miażdżycy tętnic i nadciśnienia | |
| IL173336A0 (en) | Therapeutic compounds | |
| MXPA05003104A (es) | Hidromorfonas n-sustituidas y uso de las mismas. | |
| WO2006047716A3 (en) | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease | |
| IL175974A (en) | Radiation protection plugins | |
| AU2001285318A1 (en) | Use of an aldosterone receptor antagonist to improve cognitive function | |
| HU0002509D0 (en) | Combination therapy for treatment of migraine | |
| AU2003210730A8 (en) | Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders | |
| SI1608655T1 (sl) | Derivati piroloimidazola, njihova priprava, farmacevtske sestave, ki jih vsebujejo, in njihova rabakot nutropiäśnih sredstev | |
| IL145237A0 (en) | Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease | |
| AU1604001A (en) | Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects | |
| HRP20030609A2 (en) | Use of il-18 inhibitors for the treatment and/or prevention of heart disease | |
| PL371437A1 (en) | Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions | |
| IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
| MXPA04008460A (es) | Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista de receptor de histamina. | |
| PL375564A1 (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma | |
| IL144216A0 (en) | Use of angiotensin ii receptor antagonists for treating acute myocardial infarction | |
| HU0002508D0 (en) | Combination therapy for treatment of migraine | |
| GB0606985D0 (en) | Therapeutic agents | |
| IL158091A0 (en) | Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders | |
| PL371436A1 (en) | Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders | |
| IL143903A0 (en) | Use of phanquinone for the treatment or prevention of memory impairment | |
| AU2003245995A8 (en) | Use of gaba-c receptor antagonists for the treatment of myopia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |